Method for facilitating transmucosal delivery of steroidal active agents

ABSTRACT

A buccal dosage unit is provided for administering a combination of steroidal active agents to a female individual. The novel buccal drug delivery systems may be used in female hormone replacement therapy, in female contraception, to treat female sexual dysfunction, and to treat or prevent a variety of conditions and disorders which are responsive to the active agents discussed herein. The buccal dosage unit comprises a progestin, an estrogen and optionally an androgenic agent, as well as a polymeric carrier that bioerodes and provides for delivery of the active agents throughout a predetermined drug delivery period.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No.09/237,713, filed Jan. 26, 1999, now U.S. Pat. No. 6,117,446.

TECHNICAL FIELD

This invention relates generally to pharmaceutical compositions andmethods for administering pharmacologically active agents. Moreparticularly, the invention relates to buccal drug delivery, and to abuccal dosage unit and method for administering a combination ofsteroidal active agents, e.g., for female hormone replacement therapy,female contraception, treatment of female sexual dysfunction, and thelike.

BACKGROUND

Androgens are the hormones that cause most of the masculinizing changesthat occur in males during puberty. Harrison's Principles of InternalMedicine, 12^(th) Edition (New York, N.Y.: McGraw Hill, Inc., 1991).However, low levels of androgens are also present in normal females.Testosterone and other androgens are secreted by the ovary and theadrenal cortex. See, e.g., Goodman & Gilman's The Pharmacological Basisof Therapeutics, 9^(th) Edition (New York, N.Y.: McGraw Hill, Inc.,1996). Dehydroepiandrosterone (DHEA) and androstenedione are alsosynthesized by both the adrenal gland and the ovary and can be convertedto testosterone or estrogen in peripheral tissues. The daily rate ofproduction of testosterone in women is on the order of 0.25 mg, abouthalf of which is derived from the metabolic conversion ofandrostenedione to testosterone at extraglandular sites. The plasmaconcentration of testosterone in women alters with the menstrual cycleand ranges from 15 to 65 nanogram/deciliter (ng/dl). As with estrogen,testosterone levels peak at the preovulatory and luteal phases of thecycle. At menopause, plasma androgen and estrogen levels are reduced butnot completely absent in women. Alteration in the hormone profile isbelieved to be an underlying cause of menopausal symptoms in women,including vasomotor instability (“hot flash”), atrophy of the urogenitalepithelium and skin, decreased size of the breasts and osteoporosis.See, e.g., Harrison 's Principles of Internal Medicine, supra.

Alteration in normal hormonal levels can also cause sexual dysfunction.For example, estrogen deficiency, causing vaginal atrophy anddyspareunia, is a common cause of sexual dysfunction. Dyspareunia isthought to affect approximately 40% of women; it has been estimated thatover 40 million female individuals will suffer dyspareunia at some timein their lives. On the order of twenty-five million women willexperience dyspareunia in the peri- and postmenopausal periods (Kelly(1992) Clinical Practice and Sexuality 8(8):2; and Sato et al. (1992)Clinical Practices in Sexuality 8(5):1.

Estrogen therapy is commonly used in the pharmacological treatment ofaltered hormone profiles or sexual dysfunction in women. Estrogen-basedtherapies are generally used to increase mucous production, providevasodilator effects, and/or to increase the general health of thevagina. Nadelson et al., eds., Treatment Interventions in HumanSexuality (New York: Plenum Press, 1983). In such treatments, estrogenis administered orally, parenterally (e.g., by injection), or topically.With oral administration, as is true with the oral administration ofmany steroid hormones, estrogens tend to be inactivated; estradiol, forexample, is converted to estriol and estrone and then conjugated toglucuronic acid or sulfate. Additionally, estrogens also impair hepaticsecretory activity. This “first pass” effect may lead to an undesirableincrease in the production of certain coagulation factors and otherbiologically important compounds by the liver. Parenterally administeredestrogen avoids the aforementioned problems associated with oraladministration. However, all estrogen-based therapies are known toincrease the risk of endometrial hyperplasia and cancer, as well as therisk of breast cancer, in treated individuals.

Because of the increased risk of endometrial hyperplasia and endometrialcancer encountered with unopposed estrogen therapies, estrogen/progestincombinations have been employed. However, such therapies, as is wellknown, result in a number of side effects, including uterine bleedingand the continuation of menstrual periods. Accordingly, there remains aneed in the art to provide safer and more effective treatments foradministering active agents suitable for female hormone replacementtherapy.

The present invention is directed in part to the aforementioned need inthe art, and provides highly effective hormone replacement therapy forwomen in need of such treatment. The invention involves the use of apharmaceutical composition in the form of a drug dosage unit to beapplied to the buccal mucosa. In contrast to prior methods for effectinghormone replacement, the present invention avoids both gastrointestinaldegradation of the drug and the “first pass” effect in the liverencountered with oral formulations, and enables the use of smaller dosesof active agents (and thus avoids the side effects associated withconventional formulations). In addition, when an androgenic agent isincluded, as in the preferred embodiment herein, essentially completehormone replacement is provided. That is, with respect to the latterpoint, estrogen/progestin therapies do not in fact provide “replacement”of the complete hormone profile of the premenopausal woman, because, asdiscussed above, androgens are also present in premenopausal women. In apreferred embodiment, then, the present invention calls for one or moreandrogenic agents to be administered along with a progestin and anestrogen.

The method and compositions of the invention may also be used to treatother conditions for which the disclosed hormone combination is useful.For example, the novel drug dosage units can be used to treat femalesexual dysfunction, to effect female contraception, to improve vaginalmuscle tone and tissue health, and to enhance vaginal lubrication.

Drug therapy for treating female sexual dysfunction has been described.For example, U.S. Pat. No. 4,507,323 to Stern describes the use of theanxiolytic m-chloro-α-t-butylamino-propiophenone in the treatment ofsexual dysfunction in male and female individuals. Pharmaceuticalcompositions containing the agent are described, which are presented indiscrete units, e.g., cachets, tablets, capsules, ampules andsuppositories for oral or anal delivery of the agent. Additionally, U.S.Pat. No. 4,521,421 to Foreman describes the treatment of sexualdysfunction in male and female individuals using the stereoisomers ofoctahydro-pyrimidoquinoline agents, centrally acting dopamine agonists.U.S. Pat. No. 5,190,967 to Riley describes the treatment of sexualdisorders in male and female individuals using heterocyclicbenzodioxinopyrrole compounds, which, like the drugs described in theaforementioned patents, are centrally acting agents.

Drug therapy involving buccal administration of steroid hormones hasalso been described. For example, U.S. Pat. No. 4,755,386 to Hsiao etal. generally describes the buccal administration of variousmedicaments, including estrogens, progestins and androgens; combinationsof the medicaments, however, are not contemplated. Furthermore, thebuccal tablets of Hsiao et al., weighing on the order of 50 mg, containadhesive, disintegrant and excipient in addition to the active agent,with the inactive ingredients representing up to about 90 wt. % of theformulation. U.S. Pat. No. 4,764,378 to Keith et al. describes rapidlydisintegrating dosage forms utilizing a combination of high and lowmolecular weight polyethylene glycols; the dosage forms, which arepreferably 50 mg to 100 mg tablets, may be administered orally orthrough the buccal mucosa. Similarly, U.S. Pat. No. 5,135,752 to Snipeset al. describes buccal delivery systems containing polyethylene glycolsof varying molecular weights for the delivery of methyl testosterone orestradiol. In U.S. Pat. No. 4,877,774 to Pitha et al., crystallinecomplexes of steroid hormones and gamma-cyclodextrin are described foradministration of steroids through mucosal tissue.

The buccal drug dosage units and methods of the present invention are,however, new and completely unsuggested by the art. Applicants'invention is premised on the discovery that steroidal agents,particularly an androgenic agent in combination with an estrogen and aprogestin, can be buccally administered to provide for a highlyeffective method of female hormone replacement therapy. The buccaldosage units provided herein can also be used for other purposes, e.g.,treatment of female sexual dysfunction, female contraception,improvement of vaginal muscle tone and tissue health, enhancement ofvaginal lubrication, and the like.

SUMMARY OF THE INVENTION

Accordingly, it is a primary object of the invention to address theaforementioned need in the art by providing a drug dosage unit forbuccally administering to a female individual a pharmaceuticalcomposition comprising an estrogenic agent and a progestin, optionallyin further combination with an androgenic agent.

It is another object of the invention to provide a method foradministering a combination of steroidal agents to a female individualusing the aforementioned drug dosage unit.

It is still another object of the invention to provide a method forfacilitating delivery of a combination of steroidal active agents to anindividual comprising affixing to the buccal mucosa of the individual adosage unit as described herein and allowing the dosage unit to remainin place until erosion thereof is complete.

It is yet another object of the invention to provide female hormonereplacement therapy by buccally administering a pharmaceuticalcomposition as described herein to a woman in need of such therapy.

It is a further object of the invention to provide a method foreffecting contraception in a fertile mammalian female by buccallyadministering a pharmaceutical composition as described herein.

It is still a further object of the invention to treat female sexualdysfunction by buccally administering a combination of active agents asdescribed herein to a woman in need of such treatment.

It is an additional object of the invention to provide methods forimproving vaginal muscle tone and tissue health and for enhancingvaginal lubrication, each of such methods involving buccaladministration of a pharmaceutical composition as described herein to awoman in need of such treatment.

Additional objects, advantages and novel features of the invention willbe set forth in part in the description which follows, and in part willbecome apparent to those skilled in the art upon examination of thefollowing, or may be learned by practice of the invention.

Accordingly, in a first embodiment, a pharmaceutical composition isprovided in the form of a simple, compact buccal dosage unit comprisingtherapeutically effective amounts of an androgenic agent, a progestinand an estrogen, or therapeutically effective amounts of an estrogen anda progestin, in a bioerodible polymeric carrier, wherein the carrier issuch that it enables the dosage unit to adhere to the buccal mucosa.Following application to the buccal mucosa, gradual and complete erosionof the unit occurs over a predetermined time period, thus providing drugdelivery throughout that time period. In a preferred embodiment, thedosage unit contains only the active agents to be administered and thepolymeric carrier. However, other components, particularly a lubricant,may be incorporated to facilitate manufacture of the unit or ifotherwise found to be necessary or desirable. The buccal dosage unitsare typically far smaller than conventional buccal delivery systems—thepresent tablets are on the order of 5-20 mg, typically 10-15 mg— and donot require a plurality of excipients, disintegrants, adhesives, or thelike, nor are fragrances or permeation enhancers necessary. Accordingly,the novel dosage units are more comfortable than conventional systemsbecause of their compact size. The novel units are also highly effectivein providing therapeutically effective levels of steroidal agents. Whilethe dosage units are designed to erode and thus deliver the activeagents over a predetermined time period that is generally in the rangeof about 8 hours to about 24 hours, 12-hour dosage units are preferred,such that the individual receiving drug therapy can conveniently use twodosage units in a 12-hour period, enabling two “breaks” for dentalhygiene or the like during the day. In this regard, the dosage units canbe applied to an area of a subject's buccal mucosa such that the subjectcan eat and/or drink with the unit in place.

In another aspect of the invention, a method is provided foradministering a combination of steroidal agents to a female individualusing the aforementioned buccal dosage units, to treat any disorder,condition, disease or dysfunction for which the combination of anestrogen, a progestin, and, optionally, an androgenic agent, beindicated. The combination of active agents may be administered, forexample, to provide female hormone replacement therapy, to effect femalecontraception, to treat female sexual dysfunction, to improve vaginalmuscle tone and tissue health, to enhance vaginal lubrication, and thelike. The active agents are administered through the buccal mucosa byaffixing a dosage unit as provided herein to the buccal mucosa of theindividual undergoing treatment, and allowing the dosage unit to remainin place until erosion thereof and thus drug delivery is complete.Preferably, the dosage unit is affixed to the upper gum area in a regiondefined as extending from the first bicuspid on the left to the firstbicuspid on the right; an alternative preferred location for the dosageunit is the inner lip area opposing the aforementioned gum area.

A further embodiment of the invention relates to a kit for assisting anindividual in buccal drug administration. Generally, the kit includesthe following components: a buccal dosage unit comprising a combinationof steroidal active agents in a bioerodible polymeric carrier; acontainer housing the dosage unit prior to use; and written instructionsfor carrying out administration of the active agents for the intendedtherapeutic purpose.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 schematically illustrates one embodiment of a buccal dosage unitaccording to the invention.

FIG. 2 schematically illustrates an alternative and preferred embodimentof a buccal dosage unit according to the invention.

FIG. 3 schematically illustrates a second alternative embodiment of abuccal dosage unit according to the invention.

FIG. 4 illustrates the placement of the buccal dosage unit in thepreferred location in the oral cavity.

DETAILED DESCRIPTION OF THE INVENTION

Before describing the present invention in detail, it is to beunderstood that this invention is not limited to specific active agentsor carriers as such may vary. It is also to be understood that theterminology used herein is for the purpose of describing particularembodiments only, and is not intended to be limiting.

It must be noted that, as used in this specification and the appendedclaims, the singular forms “a”, “an” and “the” include plural referentsunless the context clearly dictates otherwise. Thus, for example,reference to “an estrogen” or “an estrogenic agent” includes a mixtureof two or more such active agents, reference to “a buccal permeationenhancer” includes mixtures of two or more enhancers, reference to “acarrier” or “an excipient” includes a combination of two or more suchmaterials, and the like.

In describing and claiming the present invention, the followingterminology will be used in accordance with the definitions set outbelow.

The terms “drug” or “pharmacologically active agent” or “active agent”are used interchangeably herein to refer to a compound or composition ofmatter which, when administered to an organism (human or animal) inducesa desired pharmacologic and/or physiologic effect by local and/orsystemic action. The active agents herein are steroid hormones,including androgenic agents, e.g., testosterone and derivatives,analogs, esters and salts thereof, progestins (also referred to hereinand in the art as “progestogens”), e.g., progesterone and the like, andestrogens, e.g., ethynyl estradiol and the like.

By “buccal” drug delivery is meant delivery of a drug by passage of adrug through the buccal mucosa into the bloodstream. Preferably, buccaldrug delivery is effected herein by placing the buccal dosage unit onthe upper gum or opposing inner lip area of the individual undergoingdrug therapy.

“Penetration enhancement” or “permeation enhancement” as used hereinrelates to an increase in the permeability of the buccal mucosal tissueto a pharmacologically active agent, i.e., so that the rate at which thedrug permeates through the mucosal tissue is increased.

“Excipients” or “vehicles” as used herein refer to any excipients orvehicles suitable for buccal drug administration, and include any suchmaterials known in the art, e.g., any liquid, gel, solvent, liquiddiluent, solubilizer, or the like, which is nontoxic and does notinteract with other components of the composition in a deleteriousmanner.

By an “effective” or “therapeutically effective” amount of a drug orpharmacologically active agent is meant a nontoxic but sufficient amountof the drug or agent to provide the desired effect. An “effective”amount of a permeation enhancer as used herein means an amount that willprovide the desired increase in the rate at which an active agent passesthrough the tissue of the buccal mucosa. “Compact” as used herein refersto a buccal dosage unit that is preferably no larger than about 5 mm indiameter and 2 mm in height, so that the unit occupies at most about 40mm³, typically weighs less than about 40 mg (preferably 5 to 20 mg, morepreferably 10 to 15 mg), and has a contact surface area of no more thanapproximately 20 mm³.

The terms “erodible” and “bioerodible” as used herein refer to acompound or composition that hydrolyzes upon contact with the buccalmucosa.

By “female sexual dysfunction” is meant any and all types of sexualdysfunction in human females, including, but not limited to, excitementstage dysfunctions such as touch sensation impairment, loss of clitoralsensation, and vaginal dryness and concomitant dyspareunia. Other typesof female sexual dysfunction are discussed in detail by Kaplan, TheEvaluation of Sexual Disorders: Psychological and Medical Aspects (NewYork, N.Y.: Bruriner-Mazel, 1983), and by Kolodny et al., Textbook ofSexual Medicine (Boston, Mass.: Little, Brown & Co., 1979). Referencemay be had to those texts for information not explicitly discussedherein.

The terms “treating” and “treatment” as used herein refer to reductionin severity and/or frequency of symptoms, elimination of symptoms and/orunderlying cause, prevention of the occurrence of symptoms and/or theirunderlying cause, and improvement or remediaton of damage. Thus, forexample, the present method of “treating” female sexual dysfunction, asthe term “treating” is used herein, encompasses both prevention offemale sexual dysfunction and treatment of the dysfunction in aclinically symptomatic individual.

In one embodiment, then, a pharmaceutical composition is provided in theform of a buccal dosage unit for the administration of a combination ofsteroidal agents. The dosage unit comprises (a) therapeuticallyeffective amounts of an androgenic agent, a progestin and an estrogen,or of a progestin and an estrogen, and (b) a bioerodible polymericcarrier as will be described in detail below. The dosage unit isfabricated so as to erode gradually over a predetermined time period,wherein drug delivery is provided essentially throughout. The timeperiod is typically in the range of 8 hours to 24 hours; that is, for an8-hour unit, erosion will occur throughout an 8-hour period and besubstantially complete at the 8-hour point, while for a 24-hour unit,erosion will occur throughout a 24-hour period and be substantiallycomplete at the 24-hour point. The buccal dosage unit may furthercomprise a lubricant to facilitate manufacture, e.g., magnesium stearateor the like. Additional components that may be included in the buccaldosage unit, but are neither required nor preferred, are flavorings,permeation enhancers, diluents, binders, and the like. As a buccal drugdelivery system, the novel dosage unit avoids the disadvantagesencountered with oral drug administration, e.g., degradation of theagents by fluids present in the gastrointestinal tract and/or first-passinactivation in the liver. In addition, because of its compact size, theunit is not associated with the discomfort encountered with larger,conventional buccal drug delivery systems. Also, the units areconvenient in that the wearer need change the unit only once or twicedaily, i.e., with 24-hour or 12-hour systems, respectively; a 12-hourunit to be applied once in the morning and once in the evening isoptimal. Finally, because of the compositional simplicity of the unit—ina preferred embodiment, the unit contains only the active agents and thepolymeric carrier—manufacture of the dosage form is straightforward andeconomical.

The buccal dosage units of the invention are useful in providingeffective female hormone replacement therapy, in that the occurrence ofsymptoms or conditions resulting from altered hormone levels ismitigated or substantially prevented. The invention is thus useful totreat women for whom ovarian steroid production has been altered, eitherbecause of menopause, surgical or radiation treatment, ovarian ablation,or premature ovarian failure. As noted elsewhere herein, the inventionis also useful to treat female sexual dysfunction, to effect femalecontraception, to improve vaginal muscle tone and tissue health, and forenhancing vaginal lubrication. Each buccal dosage unit will contain anandrogenic agent, a progestin, and an estrogen, or a progestin and anestrogen.

Suitable androgenic agents that may be used in the formulations of thepresent invention include, but are not limited to: the naturallyoccurring androgens and derivatives thereof, including androsterone,androsterone acetate, androsterone propionate, androsterone benzoate,androstenediol, androstenediol-3-acetate, androstenediol-17-acetate,androstenediol-3,17-diacetate, androstenediol-17-benzoate,androstenediol-3-acetate-17-benzoate, androstenedione,dehydroepiandrosterone (DHEA; also termed “prasterone”), sodiumdehydroepiandrosterone sulfate, 4-dihydrotestosterone (DHT; also termed“stanolone”), 5α-dihydrotestosterone, dromostanolone, dromostanolonepropionate, ethylestrenol, nandrolone phenpropionate, nandrolonedecanoate, nandrolone furylpropionate, nandrolone cyclohexanepropionate,nandrolone benzoate, nandrolone cyclohexanecarboxylate, oxandrolone,stanozolol and testosterone; pharmaceutically acceptable esters oftestosterone and 4-dihydrotestosterone, typically esters formed from thehydroxyl group present at the C-17 position, including, but not limitedto, the enanthate, propionate, cypionate, phenylacetate, acetate,isobutyrate, buciclate, heptanoate, decanoate, undecanoate, caprate andisocaprate esters; and pharmaceutically acceptable derivatives oftestosterone such as methyl testosterone, testolactone, oxymetholone andfluoxymesterone. Testosterone and testosterone esters, such astestosterone enanthate, testosterone propionate and testosteronecypionate, are particularly preferred androgenic agents for use inconjunction with the present invention. The aforementioned testosteroneesters are commercially available or may be readily prepared usingtechniques known to those skilled in the art or described in thepertinent literature. (Generally, the 17-hydroxyl group of thetestosterone molecule is caused to react with a suitable organic acidunder esterifying conditions, such conditions typically involving theuse of a strong acid such as sulfuric acid, hydrochloric acid, or thelike, and a temperature sufficient to allow the reaction to proceed atreflux.)

Suitable estrogens that may be administered using the dosage units ofthe invention include synthetic and natural estrogens such as: estradiol(i.e., 1,3,5-estratriene-3,17β-diol, or “β-estradiol”) and its esters,including estradiol benzoate, valerate, cypionate, heptanoate,decanoate, acetate and diacetate; 17α-estradiol; ethynylestradiol (i.e.,17α-ethynylestradiol) and esters and ethers thereof, includingethynylestradiol 3-acetate and ethynylestradiol 3-benzoate; estriol andestriol succinate; polyestrol phosphate; estrone and its esters andderivatives, including estrone acetate, estrone sulfate, and piperazineestrone sulfate; quinestrol; mestranol; and conjugated equine estrogens.Estradiol and ethynylestradiol are particularly preferred syntheticestrogenic agents for use in conjunction with the present invention.

Suitable progestins for use in the buccal drug delivery units of theinvention include, but are not limited to, acetoxypregnenolone,allylestrenol, anagestone acetate, chlormadinone acetate, cyproterone,cyproterone acetate, desogestrel, dihydrogesterone, dimethisterone,ethisterone (17α-ethynyltestosterone), ethynodiol diacetate,flurogestone acetate, gestadene, hydroxyprogesterone,hydroxyprogesterone acetate, hydroxyprogesterone caproate,hydroxymethylprogesterone, hydroxymethylprogesterone acetate,3-ketodesogestrel, levonorgestrel, lynestrenol, medrogestone,medroxyprogesterone acetate, megestrol, megestrol acetate, melengestrolacetate, norethindrone, norethindrone acetate, norethisterone,norethisterone acetate, norethynodrel, norgestimate, norgestrel,norgestrienone, normethisterone, and progesterone. Progesterone,cyproterone acetate, norethindrone, norethindrone acetate andlevonorgestrel are preferred progestins.

The aforementioned steroidal agents are selected from the groupconsisting of naturally occurring steroids, synthetic steroids, andderivatives thereof. The active agents may be incorporated into thepresent dosage units and thus administered in the form of apharmaceutically acceptable derivative, analog, ester or salt, or theagents may be modified by appending one or more appropriatefunctionalities to enhance selected biological properties such aspenetration through the mucosal tissue. In general, when the buccaldosage units are used to administer androgenic agents, esters arepreferred relative to salts or other derivatives. Preparation of estersinvolves functionalization of hydroxyl and/or carboxyl groups that maybe present, as will be appreciated by those skilled in the arts ofpharmaceutical chemistry and drug delivery. Esters can be reconverted tothe free acids, if desired, by using conventional hydrogenolysis orhydrolysis procedures.

To administer any one of the active agents in salt form, suitablepharmaceutically acceptable salts can be prepared using standardprocedures known to those skilled in the art of synthetic organicchemistry and described, for example, by J. March, Advanced OrganicChemistry: Reactions, Mechanisms and Structure, 4th Ed. (New York:Wiley-Interscience, 1992). Acid addition salts are prepared from anactive agent in the free base form (e.g., compounds having a neutral—NH₂ group) using conventional means, involving reaction with a suitableacid. Suitable acids for preparing acid addition salts include bothorganic acids, e.g., acetic acid, propionic acid, glycolic acid, pyruvicacid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid,fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid,mandelic acid, methanesulfonic acid, ethanesulfonic acid,p-toluenesulfonic acid, salicylic acid, and the like, as well asinorganic acids, e.g., hydrochloric acid, hydrobromic acid, sulfuricacid, nitric acid, phosphoric acid, and the like. An acid addition saltmay be reconverted to the free base by treatment with a suitable base.Preparation of basic salts of acid moieties which may be present (e.g.,carboxylic acid groups) are prepared in a similar manner using apharmaceutically acceptable base such as sodium hydroxide, potassiumhydroxide, ammonium hydroxide, calcium hydroxide, magnesium hydroxide,trimethylamine, or the like.

For those active agents that are chiral in nature and can thus be inenantiomerically pure form or in a racemic mixture, the drug may beincorporated into the present dosage units either as the racemate or inenantiomerically pure form.

The quantity of each active agent in the buccal dosage unit will dependon a number of factors, including the potency of each agent and theintended dosage, which, in turn, is dependent on the particularindividual undergoing treatment, the specific indication, and the like.Generally, when present the androgenic agent represents approximately 5wt. % to 20 wt. %, preferably 10 wt. % to 20 wt. %, of the buccal dosageunit, the progestin represents approximately 5 wt. % to 60 wt. %,preferably 30 wt. % to 60 wt. %, of the dosage unit, and the estrogenrepresents approximately 1 wt. % to 5 wt. %, preferably 2 wt. % to 5 wt.%, of the buccal dosage unit. The remainder of the buccal dosage unitcomprises the bioerodible polymeric carrier, as will be described indetail below, and any excipients that may be desired, e.g., binders,disintegrants, lubricants, diluents, flavorings, colorings, and thelike, and/or additional active agents.

Ideally, the carrier comprises a polymer having sufficient tack toensure that the dosage unit adheres to the buccal mucosa for thenecessary time period, i.e., the time period during which thecombination of active agents is to be delivered to the buccal mucosa.Additionally,. the polymeric carrier is gradually “bioerodible,” i.e.,the polymer hydrolyzes at a predetermined rate upon contact withmoisture. The polymeric carrier is preferably sticky when moist, but notwhen dry, for convenience in handling. Generally, it is preferred thatthe weight average molecular weight (M_(w)) of the polymer be in therange of approximately 4,000 to 1,000,000, more preferably in the rangeof approximately 100,000 to 1,000,000. One of skill in the art willappreciate that the higher the molecular weight of the polymer, theslower the erosion time.

Any polymeric carriers can be used that are pharmaceutically acceptable,provide both a suitable degree of adhesion and the desired drug releaseprofile, and are compatible with the agents to be administered and anyother components that may be present in the buccal dosage unit.Generally, the polymeric carriers comprise hydrophilic (water-solubleand water-swellable) polymers that adhere to the wet surface of thebuccal mucosa. Examples of polymeric carriers useful herein includeacrylic acid polymers and copolymers, e.g., those known as “carbomers”(Carbopol®, which may be obtained from B. F. Goodrich, is one suchpolymer). Other suitable polymers include, but are not limited to:hydrolyzed polyvinylalcohol; polyethylene oxides (e.g., Sentry Polyox®water soluble resins, available from Union Carbide); polyacrylates(e.g., Gantrez®, which may be obtained from GAF); vinyl polymers andcopolymers; polyvinylpyrrolidone; dextran; guar gum; pectins; starches;and cellulosic polymers such as hydroxypropyl methylcellulose (e.g.,Methocel®, which may be obtained from the Dow Chemical Company),hydroxypropyl cellulose (e.g., Klucel®, which may also be obtained fromDow), hydroxypropyl cellulose ethers (see, e.g., U.S. Pat. No. 4,704,285to Alderman), hydroxyethyl cellulose, sodium carboxymethyl cellulose,methyl cellulose, ethyl cellulose, cellulose acetate phthalate,cellulose acetate butyrate, and the like. The carrier may also comprisetwo or more suitable polymers in combination, for example, a carbomercombined in an approximately 1:5 to 5:1 ratio, by weight, with apolyethylene oxide.

It is preferred that the present dosage unit contain only the activeagents and the polymeric carrier. However, it may be desirable in somecases to include one or more additional components. For example, alubricant may be included to facilitate the process of manufacturing thedosage units; lubricants may also optimize erosion rate and drug flux.If a lubricant is present, it will represent on the order of 0.01 wt. %to about 2 wt. %, preferably about 0.01 wt. % to 0.5 wt, %, of thedosage unit. Suitable lubricants include, but are not limited to,magnesium stearate, calcium stearate, stearic acid, sodiumstearylfumarate, talc, hydrogenated vegetable oils and polyethyleneglycol. As will be appreciated by those skilled in the art, however,modulating the particle size of the components in the dosage unit and/orthe density of the unit can provide a similar effect—i.e., improvedmanufacturability and optimization of erosion rate and drug flux—withoutaddition of a lubricant.

Other components may also be incorporated into the buccal dosage unit;however, it must be emphasized that such components are neither requirednor preferred. Such additional optional components include, for example,one or more disintegrants, diluents, binders, enhancers, or the like.Examples of disintegrants that may be used include, but are not limitedto, cross-linked polyvinylpyrrolidones, such as crospovidone (e.g.,Polyplasdone® XL, which may be obtained from GAF), cross-linkedcarboxylic methylcelluloses, such as croscarmelose (e.g., Ac-di-sol®,which may be obtained from FMC), alginic acid, and sodium carboxymethylstarches (e.g., Explotab®, which may be obtained from Edward Medell Co.,Inc.), agar bentonite and alginic acid. Suitable diluents are thosewhich are generally useful in pharmaceutical formulations prepared usingcompression techniques, e.g., dicalcium phosphate dihydrate (e.g.,Di-Tab®, which may be obtained from Stauffer), sugars that have beenprocessed by cocrystallization with dextrin (e.g., co-crystallizedsucrose and dextrin such as Di-Pak®, which may be obtained from Amstar),lactone, calcium phosphate, cellulose, kaolin, mannitol, sodiumchloride, dry starch, powdered sugar and the like. Binders, if used, arethose that enhance adhesion. Examples of such binders include, but arenot limited to, starch, gelatin and sugars such as sucrose, dextrose,molasses, and lactose. Permeation enhancers may also be present in thenovel dosage units in order to increase the rate at which the activeagents pass through the buccal mucosa. Examples of permeation enhancersinclude, but are not limited to, dimethylsulfoxide (“DMSO”), dimethylformamide (“DMF”), N,N-dimethylacetamide (“DMA”), decylmethylsulfoxide(“C₁₀MSO”), polyethylene glycol monolaurate (“PEGML”), glycerolmonolaurate, lecithin, the 1-substituted azacycloheptan-2-ones,particularly 1-n-dodecylcyclazacycloheptan-2-one (available under thetrademark Azone® from Nelson Research & Development Co., Irvine,Calif.), lower alkanols (e.g., ethanol), SEPA® (available from MacrochemCo., Lexington, Mass.), cholic acid, taurocholic acid, bile salt typeenhancers, and surfactants such as Tergitol®, Nonoxynol-9® andTWEEN-80®. Preferred dosage units of the invention, however, do notcontain permeation enhancers.

Flavorings are not typically needed in the present drug dosage units, asthe active agents do not, in general, have any taste. If for some reasona flavoring is desired, any suitable flavoring may be used, e.g.,mannitol, lactose or artificial sweeteners such as aspartame. Coloringagents may be added, although again, such agents are not required.Examples of coloring agents include any of the water soluble FD&C dyes,mixtures of the same, or their corresponding lakes.

In addition, if desired, the present dosage units may be formulated withone or more preservatives or bacteriostatic agents, e.g., methylhydroxybenzoate, propyl hydroxybenzoate, chlorocresol, benzalkoniumchloride, or the like.

Also, one or more additional types of drugs, i.e., pharmacologicallyactive agents other than androgenic agents, progestins and estrogens,may be incorporated into the present dosage units.

In general, the dosage unit of the invention is compositionally asubstantially homogeneous, substantially uniform formulation. By“substantially uniform” is meant that the dosage unit is not coated,does not have a backing, and does not contain a plurality of layers orother types of discrete segments. Rather, the substance of the dosageunit is similar throughout, so that the unit is essentially “monolithic”in nature.

In another embodiment of the invention, a method is provided foradministering a combination of steroidal agents using the buccal dosageunits described hereinabove, containing an androgenic agent, aprogestin, and an estrogen, or a progestin and an estrogen. The methodgenerally comprises buccally administering the combination of activeagents by affixing the dosage unit of the invention to the buccal mucosaof the individual and allowing the dosage unit to remain in place untilerosion thereof— and thus drug delivery— is complete. Administration ofa combination of steroidal active agents in this way is useful in avariety of contexts, as will be readily appreciated by those skilled inthe art. For example, the buccal administration of the aforementionedcombinations of steroidal agents may be used in female hormonereplacement therapy, so that the symptoms or conditions resulting fromaltered hormone levels is mitigated or substantially prevented. Asalluded to above, the method is also useful in other contexts, e.g.,treatment of female sexual dysfunction, effecting female contraception,improving vaginal muscle tone and tissue health, and enhancing vaginallubrication. The buccal dosage units and present method of administeringactive agents therewith are in addition useful to treat other conditionsand disorders that are responsive to buccal administration of thecombination of active agents disclosed herein. For example, theinvention is useful to treat the symptoms of premenstrual stress,osteoporosis, dry eye, the wasting syndrome accompanying AIDS (e.g.,unintentional weight loss, decrease in lean body mass) and someautoimmune diseases, including but not limited to Sjogren's syndrome(see, e.g., U. S. Pat. No. 5,639,743).

For female hormone replacement therapy, the woman undergoing treatmentwill generally be of childbearing age or older, in whom ovarianestrogen, progesterone and androgen production has been interruptedeither because of natural menopause, surgical procedures, radiation,chemical ovarian ablation or extirpation, or premature ovarian failure.Preferred dosage units for hormone replacement therapy are capable ofdelivering about 0.1 to about 2.5 mg of the selected androgenic agent,preferably testosterone or a testosterone ester, e.g., testosteroneenanthate, cypionate or propionate, about 300 to 5000 μg progestin,e.g., norethindrone, norethindrone acetate or the like, and about 50 to500 μg estrogen, e.g., estradiol, ethynyl estradiol or the like, over aperiod of about 24 hours. However, it will be appreciated by thoseskilled in the art that the desired dose of each individual active agentwill depend on the specific active agent as well as on other factors;the minimum effective dose of each active agent is of course preferred.Also, as noted above, in general, the androgenic agent when presentrepresents 5 wt. % to 20 wt. %, preferably 10 wt. % to 20 wt. %, of thebuccal dosage unit, the progestin represents approximately 5 wt. % to 60wt. %, preferably 30 wt. % to 60 wt. %, of the dosage unit, and theestrogen represents approximately 1 wt. % to 5 wt. %, preferably 2 wt. %to 5 wt. %, of the buccal dosage unit.

For hormone replacement therapy, and for the other indications describedherein including treatment of female sexual dysfunction, the buccaldosage units are preferably used consecutively so that administration ofthe active agents is substantially continuous. Buccal drugadministration according to the invention provides highly effectivefemale hormone replacement therapy. That is, the incidence and severityof hot flashes and night sweats are reduced, postmenopausal loss ofcalcium from bone is minimized, the risk of death from ischemic heartdisease is reduced, and the vascularity and health of the vaginal mucosaand urinary tract are improved. At the same time, the side effectsnormally expected and encountered with conventional hormone replacementare minimized or eliminated.

In treating female sexual dysfunction, and for the other indicationsdescribed herein, the dosage and administration period will, again, varydepending on the individual and the severity of sexual dysfunction orother condition; however, in general, the preferred dosage and treatmentregimen is as described above for hormone replacement therapy.

The buccal dosage units may be in the form of tablets made by eitherconventional compression or molding methods. See, e.g.,Remington'sPhamaceutical Sciences, 18^(th) edition (Easton, Pa.: Mack PublishingCo., 1990). Preferably, the dosage units are prepared by mixing thecomponents together and compressing the mixture into tablet form. Aswill be appreciated by those skilled in the art, the erosion rate of thedosage unit, and thus the rate of drug delivery, is controlled by threefactors: the pressure used to make the tablets, and thus the tablets'density; the carrier selected, as alluded to above; and thecarrier-to-drug ratio. Pressure, carrier and carrier-to-drug ratio maythus be varied to obtain shorter acting or longer-lived dosage units.

The dosage units may have any of the conventional shapes, for example,lozenges, disks, wafers, tablets or the like. One possible configurationis a conventional tablet shape as shown in FIG. 1, with the dosage unitindicated generally at 10, the pharmaceutical composition per se shownat 12, and the dosage unit's two parallel substantially planar surfacesshown at 14 and 16; either surface can be used to affix the unit to thebuccal mucosa. A more preferred configuration is shown in FIG. 2,wherein the dosage unit is shown generally at 18 with the composition at20, and the two opposing concave surfaces at 22 and 24; the opposingconcave surfaces allow for a suction effect and improve adhesion of theunit to the mucosal tissue. It will be appreciated, of course, that onlyone of the two surfaces need be concave to achieve the desired suctioneffect. A less preferred configuration is shown in FIG. 3, wherein thedosage unit shown generally at 26, containing pharmaceutical composition28, has opposing convex surfaces 30 and 32.

The dosage unit should have dimensions which fit conveniently into thebuccal cavity, and, as emphasized elsewhere herein, is preferably quitecompact. By way of example, suitable dimensions for the dosage unit are2 mm to about 5 mm in diameter, preferably not exceeding about 5 mm indiameter, and about 0.3 to about 2 mm in thickness, preferably about 0.5to 1.5 mm in thickness, most preferably about 0.5 to 1.1 mm inthickness. The total weight of the dosage unit may be from about 5 mg toabout 20 mg, preferably 10 mg to about 15 mg.

The buccal dosage units may also be generated by a molding process.Preferably, the final unit should have a melting point which is highenough to prevent fusion of packaged dosage units during shipping andstorage, yet low enough to permit mixing of pharmaceutical ingredientswithout significant decomposition of the active agents when beingincorporated into the molten carrier.

The preferred position for placement of the dosage unit in the buccalcavity, as illustrated in FIG. 4, is in the oral vestibule, generallyindicated at 40, on the anterior surface 42 of the gum, between themarginal gingiva 44 and the reflexion of the mucosa from the lips to thegums 46, i.e., the dosage unit 48 is preferably attached to the alveolarmucosa 50, between the two bicuspids 52 and 54 and slightly to one sideof the medial plane defined thereby. Such positioning places the dosageunit in contact with the mucosa on the internal surface of the lips 56as well as the alveolar mucosa 50. Such placement provides advantagesfor optimal drug delivery. For example, when so positioned, the dosageunit is out of the salivary flow path and is less likely to detach fromthe gum when the subject eats or drinks. Being out of the salivary flowpath allows optimal direct transmucosal delivery of the active agents,any saliva that contacts the unit resulting not in dissolution of theactive agents but, primarily, in softening the carrier. In addition,positioning the dosage unit as described minimizes mobility of theactive agents in the mouth. Furthermore, the dosage unit will be incontact with both the alveolar mucosa and the internal mucosal surfaceof the lips, resulting in hydrolysis of the carrier, and thus absorptionof the active agents through mucosa, on both sides of the tablet.

The invention also encompasses a kit for patients to carry out theaforementioned methods. The kit contains the drug to be administered ina buccal dosage unit (e.g., as shown in FIGS. 1, 2 or 3), a sealedcontainer housing the dosage unit prior to use, and written instructionsfor drug administration.

It is to be understood that while the invention has been described inconjunction with the preferred specific embodiments thereof, that theforegoing description as well as the examples which follow are intendedto illustrate and not limit the scope of the invention. Other aspects,advantages and modifications within the scope of the invention will beapparent to those skilled in the art to which the invention pertains.

EXAMPLE 1

Buccal dosage units weighing approximately 10 mg each and containingtestosterone, estradiol and progesterone as the active agents wereprepared using a tablet direct press, as follows.

Tablet Composition % BY WEIGHT WEIGHT (mg) COMPONENT 15% 1.5Testosterone (USP, micronized, Pharmacia Upjohn)  3% 0.3 Estradiol (USP,micronized, Pharmacia Upjohn) 47% 4.7 Progesterone (USP, micronized,Pharmacia Upjohn) 24.8%   2.48 Polyethylene oxide (Polyox ® WSR-303,Union Carbide) 10% 1.0 Carbomer (Carbopol ® NF) 0.2%  0.02 MagnesiumStearate 100%  10.00 mg

All components (i.e., testosterone, estradiol, polyethylene oxide,carbomer, and magnesium stearate, as set forth in the above table) werethoroughly mixed prior to tablet formation using aqueous fluid bedgranulation to provide a homogeneous mixture of active agents andexcipients. The individual dosage units were then made by applying 10 mgof the mixture into the punch die of the tablet press, and compressingthe mixed components using a pressure in the range of approximately 500to 2000 psi. Tablets having a diameter of approximately 4 mm and aheight of 1 mm were prepared. The tablets were removed from the punchdie and the weight and dimensions of the tablets were measured.

EXAMPLE 2

Buccal dosage units weighing approximately 10 mg each and containingtestosterone, ethynyl estradiol and progesterone as the active agents,were prepared using a tablet direct press, as follows.

Tablet Composition % BY WEIGHT WEIGHT (mg) COMPONENT 15% 1.5Testosterone (USP, micronized, Pharmacia Upjohn)  3% 0.3 Ethynylestradiol (USP, micronized, Pharmacia Upjohn) 47% 4.7 Progesterone (USP,micronized, Pharmacia Upjohn) 24.8%   2.48 Polyethylene oxide (Polyox ®WSR-303, Union Carbide) 10% 1.0 Carbomer (Carbopol ® NF) 0.2%  0.02Magnesium Stearate 100%  10.00 mg

All components (i.e., testosterone, ethynyl estradiol, polyethyleneoxide, carbomer, and magnesium stearate, as set forth in the abovetable) were thoroughly mixed prior to tablet formation using aqueousfluid bed granulation to provide a homogeneous mixture of active agentsand excipients. As in Example 1, the individual dosage units were thenmade by applying approximately 10 mg of the mixture into the punch dieof the tablet press, and compressing the mixed components using apressure in the range of approximately 500 to 2000 psi. Tablets having adiameter of approximately 4 mm and a height of 1 mm were prepared. Thetablets were removed from the punch die and the weight and dimensions ofthe tablets were measured.

EXAMPLE 3

Female patients in need of hormone replacement may be administered thebuccal dosage unit described in Example 1 or Example 2 every 24-hourperiod. Plasma levels of androgen, progestin and estrogen are measuredusing conventional methodology, both prior to treatment and at intervalsafter the start of treatment. The change in steroid hormone levels priorto and following treatment may be used to assess the efficacy of thehormone supplement. Based on these measurements, a determination is madeas to whether or not hormone levels have reached acceptable levels. Theindividuals' dosage may be adjusted accordingly.

EXAMPLE 4

Individual women are assessed and pre-screened to assemble anexperimental group of subjects suffering from sexual dysfunction. Thebuccal drug dosage units of Examples 1 and 2 are each assessed in theexperimental subjects for their ability to increase uterine or vaginalepithelial blood flow. Changes in blood flow or vaginal fluid productionduring and following buccal drug administration are determined usingknown methods. Increase in vaginal epithelial blood flow is determinedusing indirect methods such as photoplethysmography (Levin (1980)Clinics in Obstet. Gynaecol. 7:213-252), heated oxygen electrode (Wagneret al. (1978), “Vaginal Fluid” in The Human Vagina, Evans et al. (eds.),Amsterdam: Elsevier/North Holland Biomedical Press, pp. 121-137), anddirect clearance of radioactive Xenon (Wagner et al. (1980) Obstet.Gynaecol. 56:621-624). Changes in vulvar blood flow are monitored usinglaser Doppler velocimetry (Sarrel (1990) Obstet. GynaecoL. 75:26S-32S).

Decreased vaginal dryness and/or dyspareunia are negatively correlatedwith vaginal blood flow rates, wherein increased blood flow to thevagina correlates with increased lubrication and decreased frequency andseverity of dyspareunia (Sarrel (1990) Obstet. Gynaecol. 75:26S-32 S).Accordingly, vulvar blood flow after treatment is assessed using laserDoppler velocimetry and compared to baseline levels. Increased vaginallubrication as a result of treatment with the vasodilating formulationscan also be assessed using the methods of Semmens et al. (1982) J. Am.Med Assoc. 4:445448. The buccal dosage units of the invention, includingthe units formulated as set forth in Examples 1 and 2, substantiallyincrease blood flow to the vagina and vulvar area and alleviate vaginaldryness, as may be confirmed using the aforementioned methods.

What is claimed:
 1. A method for facilitating transmucosal delivery of acombination of steroidal active agents to an individual which comprises(a) providing a buccal dosage unit comprised of a compressed tablet of abioerodible polymeric carrier and therapeutically effective amounts ofan androgenic agent, a progestin and an estrogen; and (b) affixing thedosage unit to the buccal mucosa of the individual and allowing thedosage unit to remain in place until erosion thereof is complete.
 2. Amethod for facilitating transmucosal delivery of a combiniation ofsteroidal activc agcnts to an individual which comprises (a) providing abuccal dosage unit comprised of a compressed tablet of a bioerodiblepolymeric carrier and therapcutically effective amounts of a progestinand an estrogen; and (b) affixing the dosage unit to the buccal mucosaof the individual and allowing the dosage unit to remain in place untilerosion thereof is comliplete.
 3. The method of claim 1, wherein theandrogenic agent is selected from the group consisting of androsterone,androsterone acetate, androsterone propionate, androsterone benzoate,androstenediol, androstenediol-3-acetate, androstenediol-17-acetate,androstenediol-3,17-diacetate, androstenediol-17-benzoate,androstenediol-3-acetate-17-benzoate, androstenedione,dehydro-epiandrosterone, sodium dehydroepiandrosterone sulfate,dromostanolone, dromostanolone propionate, ethylestrenol,fluoxymesterone, methyl testosterone, nandrolone phenpropionate,nandrolone decanoate, nandrolone furylpropionate, nandrolonecyclohexane-propionate, nandrolone benzoate, nandrolonecyclohexanecarboxylate, oxandrolone, oxymetholone, stanozolol,testosterone, 4-dihydrotestosterone, 5α-dihydrotestosterone,testolactone, pharmaceutically acceptable esters and salts thereof, andcombinations of any of the foregoing.
 4. The method of claim 3, whereinthe androgenic agent is testosterone or a pharmaceutically acceptableester thereof.
 5. The method of claim 4, wherein the androgenic agent isa testosterone ester.
 6. The method of claim 5, wherein the testosteroneester is selected from the group consisting of testosterone enanthate,propionate, cypionate, phenylacetate, acetate, buciclate, heptanoate,decanoate, undecanoate, caprate and isocaprate.
 7. The method of claim6, wherein the testosterone ester is selected from the group consistingof testosterone enanthate, propionate and cypionate.
 8. The method ofclaim 4, wherein the androgenic agent is testosterone.
 9. The method ofclaim 1, wherein the progestin is selected from the group consisting ofacetoxypregnenolone, allylestrenol, anagestone acetate, chlormadinoneacetate, cyproterone, cyproterone acetate, desogestrel,dihydrogesterone, dimethisterone, ethisterone, ethynodiol diacetate,flurogestone acetate, gestadene, hydroxyprogesterone,hydroxyprogesterone acetate, hydroxyprogesterone caproate,hydroxymethylprogesterone, hydroxymethyl-progesterone acetate,3-ketodesogestrel, levonorgestrel, lynestrenol, medrogestone,medroxyprogesterone acetate, megestrol, megestrol acetate, melengestrolacetate, norethindrone, norethindrone acetate, norethisterone,norethisterone acetate, norethynodrel, norgestimate, norgestrel,norgestrienone, normethisterone, progesterone, and combinations thereof.10. The method of claim 9, wherein the progestin is selected from thegroup consisting of progesterone, cyproterone acetate, norethindrone,norethindrone acetate and levonorgestrel.
 11. The method of claim 10,wherein the progestin is progesterone.
 12. The method of claim 1,wherein the estrogen is selected from the group consisting of17α-estradiol, 17β-estradiol, ethynyl estradiol, pharmaceuticallyacceptable esters and ethers of 17α-estradiol, 17β-estradiol and ethynylestradiol, estriol, estriol succinate, polyestrol phosphate, estrone,estrone acetate, estrone sulfate, piperazine estrone sulfate,quinestrol, mestranol and conjugated equine estrogens.
 13. The method ofclaim 12, wherein the estrogen is 17β-estradiol or ethynyl estradiol.14. The method of claim 1, wherein the androgenic agent is testosterone,the progestin is progesterone, and the estrogen is 17β-estradiol orethynyl estradiol.
 15. The method of claim 1, wherein the carrier isselected such that upon sustained contact with the buccal mucosa theunit completely erodes within a predetermined drug delivery period inthe range of approximately 4 to 24 hours.
 16. The method of claim 15,wherein the carrier is selected from the group consisting of carbomers,hydrolyzed polyvinylalcohol, polyethylene oxide, polyacrylates,hydroxypropyl methylcellulose, hydroxypropyl cellulose, and combinationsthereof.
 17. The method of claim 16, wherein the carrier is polyethyleneoxide or a carbomer.
 18. The method of claim 1, wherein the dosage unithas a total weight of approximately 5 mg to 20 mg.
 19. The method ofclaim 18, wherein the dosage unit has a total weight of approximately 10mg to 15 mg.
 20. The method of claim 1, wherein the dosage unitcomprises approximately 5 wt. % to 20 wt. % androgenic agent, 5 wt. % to60 wt. % progestin, and 1 wt. % to 5 wt. % estrogen.
 21. The method ofclaim 20, wherein the dosage unit comprises approximately 10 wt. % to 20wt. % androgenic agent, 30 wt. % to 60 wt. % progestin, and 2 wt. % to 5wt. % estrogen.
 22. The method of claim 1, wherein the dosage unitcomprises a tablet having a concave surface for contacting the buccalmucosa and adhering thereto.
 23. The method of claim 1, wherein thedosage unit completely erodes within about 8 to about 24 hours afterapplication to the buccal mucosa.
 24. The method of claim 1, wherein thedosage unit is affixed to a region of the individual's upper gum betweenthe first bicuspid on the left and the first bicuspid on the right. 25.The method of claim 1, wherein the progestin is selected from the groupconsisting of acetoxypregnenolone, allylestrenol, anagestone acetate,chlormadinone acetate, cyproterone, cyproterone acetate, desogestrel,dihydrogesterone, dimethisterone, ethisterone, ethynodiol diacetate,flurogestone acetate, gestadene, hydroxyprogesterone,hydroxyprogesterone acetate, hydroxyprogesterone caproate,hydroxymethylprogesterone, hydroxymethyl-progesterone acetate,3-ketodesogestrel, levonorgestrel, lynestrenol, medrogestone,medroxyprogesterone acetate, megestrol, megestrol acetate, melengestrolacetate, norethindrone, norethindrone acetate, norethisterone,norethisterone acetate, norethynodrel, norgestimate, norgestrel,norgestrienone, normethisterone, progesterone, and combinations thereof.26. The method of claim 25, wherein the progestin is selected from thegroup consisting of progesterone, cyproterone acetate, norethindrone,norethindrone acetate and levonorgestrel.
 27. The method of claim 26,wherein the progestin is progesterone.
 28. The method of claim 1,wherein the estrogen is selected from the group consisting of17α-estradiol, 17β-estradiol, ethynyl estradiol, pharmaceuticallyacceptable esters and ethers of 17α-estradiol, 17β-estradiol and ethynylestradiol, estriol, estriol succinate, polyestrol phosphate, estrone,estrone acetate, estrone sulfate, piperazine estrone sulfate,quinestrol, mestranol and conjugated equine estrogens.
 29. The method ofclaim 28, wherein the estrogen is 17β-estradiol or ethynyl estradiol.30. The method of claim 1, wherein the progestin is progesterone and theestrogen is 17β-estradiol or ethynyl estradiol.
 31. The method of claim1, wherein the carrier is selected such that upon sustained contact withthe buccal mucosa the unit completely erodes within a predetermined drugdelivery period in the range of approximately 4 to 24 hours.
 32. Themethod of claim 31, wherein the carrier is selected from the groupconsisting of carbomers, hydrolyzed polyvinylalcohol, polyethyleneoxide, polyacrylates, hydroxypropyl methylcellulose, hydroxypropylcellulose, and combinations thereof.
 33. The method of claim 32, whereinthe carrier is polyethylene oxide or a carbomer.
 34. The method of claim1, wherein the dosage unit has a total weight of approximately 5 mg to20 mg.
 35. The method of claim 34, wherein the dosage unit has a totalweight of approximately 10 mg to 15 mg.
 36. The method of claim 1,wherein the dosage unit comprises approximately 5 wt. % to 20 wt. %androgenic agent, 5 wt. % to 60 wt. % progestin, and 1 wt. % to 5 wt. %estrogen.
 37. The method of claim 36, wherein the dosage unit comprisesapproximately 10 wt. % to 20 wt. % androgenic agent, 30 wt. % to 60 wt.% progestin, and 2 wt. % to 5 wt. % estrogen.
 38. The method of claim 1,wherein the dosage unit comprises a tablet having a concave surface forcontacting the buccal mucosa and adhering thereto.
 39. The method ofclaim 1, wherein the dosage unit completely erodes within about 8 toabout 24 hours after application to the buccal mucosa.
 40. The method ofclaim 1, wherein the dosage unit is affixed to a region of theindividual's upper gum between the first bicuspid on the left and thefirst bicuspid on the right.